Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis
Anna Raciborska
150 participants
Apr 1, 2021
INTERVENTIONAL
Conditions
Summary
Prospective, low intervention, open, single-center, non-commercial clinical trial to improve diagnostics in patients with histiocytosis by assessing the molecular profile of the tumor tissues, monitoring its presence in free-circulating DNA, and determining the efficacy of fluorodeoxyglucose (18F-FDG) in PET-CT imaging.
Eligibility
Inclusion Criteria5
- Patient under 18 years of age at the time of inclusion.
- Histopathologically confirmed or suspected histiocytosis (based on prior test results).
- Signing of informed consent for trial participation according with current legal regulations.
- Pregnancy.
- Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
max 6 MGBq/kg, no more than 100
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04943211